Herein, we describe the synthesis, docking, QSAR, and biological evaluation of two series of molecular hybrids targeting SERT, MAO-A, and D2 receptor in the pursuit of promising multi-target leads for potential MDD treatment. The gene discussed is SLC6A4; the disease is major depressive disorder.